Opus Genetics, Inc.

Ocuphire Pharma Inc. and privately held Opus Genetics Inc. announced an all-stock merger on 22 October that will create a publicly traded company focused primarily on gene therapies for inherited reti

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Taps Anima’s mRNA Platform, Immu

National Resilience, Inc. has closed a $625m series D venture capital round, bringing its total VC funding during the past 10 months to more than $1.2bn, including a previously unannounced $600m seri

The final installation of our series looking at industry leaders’ expectations for the year ahead focuses on sustainability and equity: in health care, in companies and across society as a whole. Tom